Exploring the ATN classification system using brain morphology.
ATN
Alzheimer’s disease
Amyloid
Biomarker
MRI
Memory
VBM
Voxel-based morphometry
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
13 03 2023
13 03 2023
Historique:
received:
06
06
2022
accepted:
08
02
2023
entrez:
14
3
2023
pubmed:
15
3
2023
medline:
16
3
2023
Statut:
epublish
Résumé
The NIA-AA proposed amyloid-tau-neurodegeneration (ATN) as a classification system for AD biomarkers. The amyloid cascade hypothesis (ACH) implies a sequence across ATN groups that patients might undergo during transition from healthy towards AD: A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+. Here we assess the evidence for monotonic brain volume decline for this particular (amyloid-conversion first, tau-conversion second, N-conversion last) and alternative progressions using voxel-based morphometry (VBM) in a large cross-sectional MRI cohort. We used baseline data of the DELCODE cohort of 437 subjects (127 controls, 168 SCD, 87 MCI, 55 AD patients) which underwent lumbar puncture, MRI scanning, and neuropsychological assessment. ATN classification was performed using CSF-Aβ42/Aβ40 (A+/-), CSF phospho-tau (T+/-), and adjusted hippocampal volume or CSF total-tau (N+/-). We compared voxel-wise model evidence for monotonic decline of gray matter volume across various sequences over ATN groups using the Bayesian Information Criterion (including also ROIs of Braak stages). First, face validity of the ACH transition sequence A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+ was compared against biologically less plausible (permuted) sequences among AD continuum ATN groups. Second, we evaluated evidence for 6 monotonic brain volume progressions from A-T-N- towards A+T+N+ including also non-AD continuum ATN groups. The ACH-based progression A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+ was consistent with cognitive decline and clinical diagnosis. Using hippocampal volume for operationalization of neurodegeneration (N), ACH was most evident in 9% of gray matter predominantly in the medial temporal lobe. Many cortical regions suggested alternative non-monotonic volume progressions over ACH progression groups, which is compatible with an early amyloid-related tissue expansion or sampling effects, e.g., due to brain reserve. Volume decline in 65% of gray matter was consistent with a progression where A status converts before T or N status (i.e., ACH/ANT) when compared to alternative sequences (TAN/TNA/NAT/NTA). Brain regions earlier affected by tau tangle deposition (Braak stage I-IV, MTL, limbic system) present stronger evidence for volume decline than late Braak stage ROIs (V/VI, cortical regions). Similar findings were observed when using CSF total-tau for N instead. Using the ATN classification system, early amyloid status conversion (before tau and neurodegeneration) is associated with brain volume loss observed during AD progression. The ATN system and the ACH are compatible with monotonic progression of MTL atrophy. DRKS00007966, 04/05/2015, retrospectively registered.
Sections du résumé
BACKGROUND
The NIA-AA proposed amyloid-tau-neurodegeneration (ATN) as a classification system for AD biomarkers. The amyloid cascade hypothesis (ACH) implies a sequence across ATN groups that patients might undergo during transition from healthy towards AD: A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+. Here we assess the evidence for monotonic brain volume decline for this particular (amyloid-conversion first, tau-conversion second, N-conversion last) and alternative progressions using voxel-based morphometry (VBM) in a large cross-sectional MRI cohort.
METHODS
We used baseline data of the DELCODE cohort of 437 subjects (127 controls, 168 SCD, 87 MCI, 55 AD patients) which underwent lumbar puncture, MRI scanning, and neuropsychological assessment. ATN classification was performed using CSF-Aβ42/Aβ40 (A+/-), CSF phospho-tau (T+/-), and adjusted hippocampal volume or CSF total-tau (N+/-). We compared voxel-wise model evidence for monotonic decline of gray matter volume across various sequences over ATN groups using the Bayesian Information Criterion (including also ROIs of Braak stages). First, face validity of the ACH transition sequence A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+ was compared against biologically less plausible (permuted) sequences among AD continuum ATN groups. Second, we evaluated evidence for 6 monotonic brain volume progressions from A-T-N- towards A+T+N+ including also non-AD continuum ATN groups.
RESULTS
The ACH-based progression A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+ was consistent with cognitive decline and clinical diagnosis. Using hippocampal volume for operationalization of neurodegeneration (N), ACH was most evident in 9% of gray matter predominantly in the medial temporal lobe. Many cortical regions suggested alternative non-monotonic volume progressions over ACH progression groups, which is compatible with an early amyloid-related tissue expansion or sampling effects, e.g., due to brain reserve. Volume decline in 65% of gray matter was consistent with a progression where A status converts before T or N status (i.e., ACH/ANT) when compared to alternative sequences (TAN/TNA/NAT/NTA). Brain regions earlier affected by tau tangle deposition (Braak stage I-IV, MTL, limbic system) present stronger evidence for volume decline than late Braak stage ROIs (V/VI, cortical regions). Similar findings were observed when using CSF total-tau for N instead.
CONCLUSION
Using the ATN classification system, early amyloid status conversion (before tau and neurodegeneration) is associated with brain volume loss observed during AD progression. The ATN system and the ACH are compatible with monotonic progression of MTL atrophy.
TRIAL REGISTRATION
DRKS00007966, 04/05/2015, retrospectively registered.
Identifiants
pubmed: 36915139
doi: 10.1186/s13195-023-01185-x
pii: 10.1186/s13195-023-01185-x
pmc: PMC10009950
doi:
Substances chimiques
Amyloid beta-Peptides
0
Amyloidogenic Proteins
0
tau Proteins
0
Biomarkers
0
Banques de données
DRKS
['DRKS00007966']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
50Subventions
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Alzheimers Dement (Amst). 2018 Apr 21;10:346-357
pubmed: 30175226
Brain. 2013 Sep;136(Pt 9):2697-706
pubmed: 23842566
Alzheimers Dement. 2018 Mar;14(3):340-351
pubmed: 29080407
Folia Neuropathol. 2014;52(3):211-25
pubmed: 25310732
Neurology. 2019 Apr 2;92(14):e1567-e1579
pubmed: 30842300
Neuroradiology. 2010 Aug;52(8):711-21
pubmed: 20495793
Curr Opin Psychiatry. 2018 Mar;31(2):147-152
pubmed: 29232251
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Alzheimers Dement. 2008 Jan;4(1):38-48
pubmed: 18631949
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Neurology. 2020 May 26;94(21):e2233-e2244
pubmed: 32398359
Lancet Neurol. 2003 Oct;2(10):605-13
pubmed: 14505582
Eur J Med Chem. 2018 Mar 25;148:436-452
pubmed: 29477076
Data Brief. 2017 Oct 16;15:648-657
pubmed: 29124088
Biol Psychiatry. 2021 Apr 15;89(8):786-794
pubmed: 32919611
Neuroimage. 2011 Apr 1;55(3):954-67
pubmed: 21216294
J Prev Alzheimers Dis. 2019;6(4):248-255
pubmed: 31686097
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Neurobiol Aging. 2017 May;53:1-10
pubmed: 28189924
Neurosci Lett. 1994 Jun 6;174(1):67-72
pubmed: 7970158
Biol Psychiatry. 2018 Feb 15;83(4):311-319
pubmed: 28967385
J Alzheimers Dis. 2020;74(3):829-837
pubmed: 32116257
Neuroimage Clin. 2017 Apr 03;15:15-24
pubmed: 28459000
Neuroimage. 2015 Jul 15;115:117-37
pubmed: 25936807
Lancet Neurol. 2013 Apr;12(4):357-67
pubmed: 23477989
Cochrane Database Syst Rev. 2017 Mar 22;3:CD010803
pubmed: 28328043
Ann Clin Transl Neurol. 2016 Jan 01;3(3):154-65
pubmed: 27042676
Sci Rep. 2018 May 30;8(1):8431
pubmed: 29849029
Science. 1992 Apr 10;256(5054):184-5
pubmed: 1566067
Nat Med. 2019 Feb;25(2):270-276
pubmed: 30643288
Alzheimers Res Ther. 2020 May 11;12(1):55
pubmed: 32393375
Expert Rev Neurother. 2008 Nov;8(11):1691-702
pubmed: 18986240
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
Alzheimers Dement. 2019 Sep;15(9):1208-1217
pubmed: 31399333
Nat Rev Neurol. 2019 Sep;15(9):501-518
pubmed: 31367008
Neuroimage. 2005 Oct 1;27(4):934-46
pubmed: 15979341
Ageing Res Rev. 2016 Sep;30:25-48
pubmed: 26827786
Ageing Res Rev. 2016 Sep;30:17-24
pubmed: 26812213
Cereb Cortex. 2006 Dec;16(12):1701-8
pubmed: 16400164
Nat Rev Neurol. 2015 Mar;11(3):157-65
pubmed: 25686760
Neuroimage. 2004 Oct;23(2):708-16
pubmed: 15488420
Alzheimers Dement. 2017 Oct;13(10):1154-1167
pubmed: 28322203
Nat Neurosci. 2020 Oct;23(10):1183-1193
pubmed: 32778792
Neuron. 2016 Mar 2;89(5):971-982
pubmed: 26938442
J Clin Med. 2019 Mar 11;8(3):
pubmed: 30862124
Neuron. 1991 Apr;6(4):487-98
pubmed: 1673054
Neurology. 2019 Oct 22;93(17):e1635-e1646
pubmed: 31597710
J Neurol Sci. 2012 May 15;316(1-2):21-9
pubmed: 22385679
J Neuropathol Exp Neurol. 2018 Jan 1;77(1):2-20
pubmed: 29186501
Lancet Neurol. 2019 Nov;18(11):1034-1044
pubmed: 31526625
IEEE Rev Biomed Eng. 2018;11:97-111
pubmed: 29994606
JAMA Neurol. 2014 Jan;71(1):11-22
pubmed: 24276092
Aging Dis. 2013 Feb;4(1):29-37
pubmed: 23423504
Cereb Cortex. 2004 Jan;14(1):11-22
pubmed: 14654453
Brain. 2014 Sep;137(Pt 9):2564-77
pubmed: 25012224
Ann Neurol. 2014 Aug;76(2):223-30
pubmed: 24852682
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
IEEE Trans Med Imaging. 1997 Apr;16(2):176-86
pubmed: 9101327
JAMA. 2019 Jun 18;321(23):2316-2325
pubmed: 31211344
Nat Rev Neurol. 2019 Oct;15(10):565-581
pubmed: 31501588
Alzheimers Res Ther. 2017 Feb 14;9(1):8
pubmed: 28193256
Int J Alzheimers Dis. 2012;2012:369808
pubmed: 22506132
Sci Aging Knowledge Environ. 2006 Mar 08;2006(6):re1
pubmed: 16525193
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Eur J Nucl Med Mol Imaging. 2008 Mar;35 Suppl 1:S58-69
pubmed: 18205002
Alzheimers Dement. 2020 Sep;16(9):1305-1311
pubmed: 30222945
J Neuropathol Exp Neurol. 1998 Dec;57(12):1122-30
pubmed: 9862634
Neurobiol Aging. 2011 Oct;32(10):1733-41
pubmed: 20005012
Neurology. 2020 Sep 1;95(9):e1134-e1143
pubmed: 32636322
Neurology. 2016 Aug 2;87(5):539-47
pubmed: 27371494
Int Rev Psychiatry. 2013 Dec;25(6):686-98
pubmed: 24423222
Neuroimage. 2001 Aug;14(2):298-309
pubmed: 11467904
Front Aging Neurosci. 2017 Mar 07;9:50
pubmed: 28326035
Alzheimers Res Ther. 2018 Feb 07;10(1):15
pubmed: 29415768
Alzheimers Dement. 2020 Jul;16(7):965-973
pubmed: 32489019
Alzheimers Dement. 2021 Jul;17(7):1189-1204
pubmed: 33811742
Neuroimage. 2017 Aug 15;157:448-463
pubmed: 28587897
Biomedicines. 2022 Sep 13;10(9):
pubmed: 36140362